On April 5, 2023 bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, reported that it will ring the Nasdaq Stock Market closing bell this afternoon to commemorate the Company’s 2022 initial public offering (IPO) (Press release, BioAffinity Technologies, APR 5, 2023, View Source [SID1234629827]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Thank you to Nasdaq for giving us the opportunity to participate in one of Wall Street’s most time-honored traditions," bioAffinity Technologies President and CEO Maria Zannes said. "When we ring the bell this afternoon, we will be celebrating the many milestones and scientific discoveries that led to the development of our first commercial product, CyPath Lung, which can detect lung cancer at the earliest stages when treatment options are more effective and lead to longer, healthier lives."

The Nasdaq Stock Market closing bell ceremony will run from approximately 3:45 to 4:05 p.m. Eastern time. A live stream of the event will be available at View Source and on the Nasdaq Facebook and Twitter pages.